Sandoz had hinted that further legal action was viable as it looks to introduce biosimilar competition to Amgen’s Enbrel blockbuster in the US. The Novartis subsidiary has now taken its fight to the very highest court.
Sandoz is taking one last shot to topple US patents blocking a path for its biosimilar to Amgen’s Enbrel (etanercept), filing a petition with the US Supreme Court for certiorari review of an unfavorable US Court of Appeals for the Federal Circuit decision which upheld the validity of two patents shielding the $5bn autoimmune diseases treatment.
In July last year, the Federal Circuit moved to affirm a New Jersey district court decision that held as valid...
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
